Scinai Immunotherapeutics (SCNI) Competitors $1.60 -0.13 (-7.51%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$1.65 +0.05 (+3.37%) As of 08/22/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock SCNI vs. APLM, JBIO, PPBT, GNPX, KTTA, CLDI, VYNE, SPRB, HCWB, and TCRTShould you be buying Scinai Immunotherapeutics stock or one of its competitors? The main competitors of Scinai Immunotherapeutics include Apollomics (APLM), Jade Biosciences (JBIO), Purple Biotech (PPBT), GENPREX (GNPX), Pasithea Therapeutics (KTTA), Calidi Biotherapeutics (CLDI), VYNE Therapeutics (VYNE), Spruce Biosciences (SPRB), HCW Biologics (HCWB), and Alaunos Therapeutics (TCRT). These companies are all part of the "pharmaceutical products" industry. Scinai Immunotherapeutics vs. Its Competitors Apollomics Jade Biosciences Purple Biotech GENPREX Pasithea Therapeutics Calidi Biotherapeutics VYNE Therapeutics Spruce Biosciences HCW Biologics Alaunos Therapeutics Apollomics (NASDAQ:APLM) and Scinai Immunotherapeutics (NASDAQ:SCNI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations. Which has stronger valuation and earnings, APLM or SCNI? Scinai Immunotherapeutics has higher revenue and earnings than Apollomics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApollomicsN/AN/A-$53.86MN/AN/AScinai Immunotherapeutics$660K2.42$4.80M-$9.57-0.17 Does the media favor APLM or SCNI? In the previous week, Apollomics' average media sentiment score of 0.00 equaled Scinai Immunotherapeutics'average media sentiment score. Company Overall Sentiment Apollomics Neutral Scinai Immunotherapeutics Neutral Is APLM or SCNI more profitable? Company Net Margins Return on Equity Return on Assets ApollomicsN/A N/A N/A Scinai Immunotherapeutics N/A N/A -40.60% Which has more risk and volatility, APLM or SCNI? Apollomics has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Comparatively, Scinai Immunotherapeutics has a beta of 1.86, indicating that its stock price is 86% more volatile than the S&P 500. Do insiders & institutionals have more ownership in APLM or SCNI? 19.1% of Apollomics shares are held by institutional investors. Comparatively, 58.4% of Scinai Immunotherapeutics shares are held by institutional investors. 60.9% of Scinai Immunotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryScinai Immunotherapeutics beats Apollomics on 5 of the 6 factors compared between the two stocks. Get Scinai Immunotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SCNI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SCNI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCNI vs. The Competition Export to ExcelMetricScinai ImmunotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.60M$3.11B$5.81B$9.76BDividend YieldN/A2.23%4.39%4.06%P/E Ratio-0.1721.0031.3626.05Price / Sales2.42209.44387.8788.42Price / CashN/A44.5038.0259.36Price / Book0.318.129.536.60Net Income$4.80M-$54.72M$3.26B$265.65M7 Day Performance0.63%2.62%2.14%2.00%1 Month Performance-25.23%3.25%3.22%0.46%1 Year Performance-60.49%10.82%30.18%18.88% Scinai Immunotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCNIScinai Immunotherapeutics0.4583 of 5 stars$1.60-7.5%N/A-60.5%$1.60M$660K-0.1720APLMApollomics0.059 of 5 stars$5.36-2.5%N/A-54.3%$5.90M$1.49M0.0045Positive NewsJBIOJade Biosciences1.7756 of 5 stars$6.96-5.4%$16.00+129.9%N/A$5.85MN/A-0.2320PPBTPurple Biotech1.7075 of 5 stars$2.19-3.1%$33.00+1,406.8%N/A$5.66MN/A-5.2120Gap DownGNPXGENPREX1.5935 of 5 stars$0.16-5.3%N/A-76.4%$5.39MN/A0.0020Gap UpKTTAPasithea Therapeutics0.5658 of 5 stars$0.72+0.4%N/A-84.6%$5.32MN/A-0.093Positive NewsShort Interest ↓Gap UpCLDICalidi Biotherapeutics0.7367 of 5 stars$1.69-43.7%N/A-87.1%$5.07MN/A0.0038News CoverageHigh Trading VolumeVYNEVYNE Therapeutics1.8729 of 5 stars$0.33-0.3%$6.25+1,782.5%-82.1%$5.05M$476K-0.3730SPRBSpruce Biosciences2.3315 of 5 stars$8.95-0.7%$131.25+1,366.5%-77.1%$5.03M$4.91M-9.5220News CoverageHCWBHCW Biologics2.1187 of 5 stars$3.41-4.4%$35.00+927.9%-81.6%$4.90M$2.57M-0.2440Earnings ReportAnalyst DowngradeShort Interest ↑Gap DownTCRTAlaunos Therapeutics1.0925 of 5 stars$2.17-2.9%N/A-37.7%$4.76M$10K-0.8840News CoveragePositive News Related Companies and Tools Related Companies Apollomics Alternatives Jade Biosciences Alternatives Purple Biotech Alternatives GENPREX Alternatives Pasithea Therapeutics Alternatives Calidi Biotherapeutics Alternatives VYNE Therapeutics Alternatives Spruce Biosciences Alternatives HCW Biologics Alternatives Alaunos Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SCNI) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scinai Immunotherapeutics Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Scinai Immunotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access